WASHINGTON -- Rheumatoid arthritis (RA) patients who achieved sustained remission had better long-term outcomes than those ...

Low patient satisfaction in psoriasis and psoriatic arthritis for clinicians and treatment is tied to need for better ...

Guidance particularly addresses the value of ultrasound in patient-provider shared decision-making in management of care.

As we previously reported, this August the European Commission granted approval for Celltrion’s STELARA biosimilar, STEQEYMA. Earlier this ...

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

MoonLake Immunotherapeutics (MLTX) announced that the first patients have been screened at U.S. trial sites in its global Phase 3 clinical ...

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

in patients with active psoriatic arthritis (PsA). PsA is a chronic, debilitating and progressive inflammatory condition that ...

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...